9YCQ image
Deposition Date 2025-09-19
Release Date 2026-07-29
Last Version Date 2026-07-29
Entry Detail
PDB ID:
9YCQ
Title:
First Bromodomain of BRDT liganded with inhibitor GXH-IV-076 (compound 33)
Biological Source:
Source Organism(s):
Homo sapiens (Taxon ID: 9606)
Expression System(s):
Method Details:
Experimental Method:
Resolution:
1.40 Å
R-Value Free:
0.20
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Bromodomain testis-specific p
Gene (Uniprot):BRDT
Chain IDs:A, B
Chain Length:110
Number of Molecules:2
Biological Source:Homo sapiens
Primary Citation
Structural Basis for BD1-Preferring 2,4-Disubstituted Pyrimidine BRDT Inhibitors.
J.Med.Chem. 69 11088 11108 (2026)
PMID: 41984625 DOI: 10.1021/acs.jmedchem.6c00180

Abstact

The first bromodomain of the BET protein BRDT (BRDT-BD1) possesses a unique Arg54 residue at the terminus of the ZA channel, absent in other BET family members. We explored this structural uniqueness with 23 analogs of the BET/kinase inhibitor SG3-179, each bearing an amino acid side chain to enable potential interactions between the positively charged arginine group and the negatively charged carboxylate groups. In an AlphaScreen assay, serine analog 13 showed 35-fold selectivity for BRDT-T over BRD4-T. The BRDT-BD1 cocrystal structure with glutamic acid analog 14 showed no interaction with Arg54, suggesting that the observed preference may be related to differences in the structured water molecules. Compound 13 displayed exceptional in vitro metabolic stability but had limited cellular permeability in MDCK-MDR1 cells. Compounds 13 and 14 are among the best BRDT-BD1-preferring inhibitors reported to date and demonstrate a significant step toward identifying highly selective BRDT inhibitors for male contraception.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback